Xspray Pharma

Xspray Pharma is a clinical-stage oncology company focused on developing best-in-class, improved versions of marketed Protein Kinase Inhibitor (PKI) drugs. Its core strategy leverages the patented HyNap technology platform to create amorphous solid dispersions that circumvent secondary crystalline patents, enabling earlier market entry post compound patent expiry while offering superior pharmacokinetic profiles. The company is on the cusp of its first commercial launch with Dasynoc in the US, has a pipeline of follow-on candidates, and has established key commercial partnerships to drive market penetration in the multi-billion dollar PKI segment.

Proprietary HyNap technology creates amorphous solid dispersions of Protein Kinase Inhibitors (PKIs), enhancing solubility and bioavailability to enable lower dosing, reduce variability, and mitigate food/drug interactions, while strategically circumventing secondary crystalline patents.